LRMRLarimar Therapeutics, Inc.

Nasdaq larimartx.com


$ 8.05 $ -0.85 (-9.55 %)    

Friday, 06-Sep-2024 15:59:59 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 8.05
$ 8.04 x 100
$ 8.05 x 100
-- - --
$ 2.18 - $ 13.68
788,437
na
513.64M
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-25-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-05-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-14-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-10-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-25-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-initiates-coverage-on-larimar-therapeutics-with-outperform-rating-announces-price-target-of-16

Baird analyst Joel Beatty initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Pr...

 jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

 larimar-therapeutics-selected-by-fda-to-participate-in-support-for-clinical-trials-advancing-rare-disease-therapeutics-pilot-program-for-nomlabofusp-in-friedreichs-ataxia

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medi...

 citigroup-maintains-buy-on-larimar-therapeutics-raises-price-target-to-14

Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from...

 larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-biogens-marketed-drug

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...

 jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION